RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...
Pharmaceutical Technology8 天
Imvotamab by IGM Biosciences for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).
Medscape1 天
Novel Autoantibodies Identified in Patients with Necrotizing Myopathy
The chronic inflammatory myopathies are idiopathic, meaning they have no known cause. They are thought to be autoimmune disorders, in which the body's white blood cells (that normally fight ...
Morningstar1 个月
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
“Idiopathic inflammatory myopathies are debilitating diseases that can cause muscle weakness, affect multiple organs, and have a severe impact on patients’ quality of life, including increased ...
Nature15 年
Polymyositis therapy: is there a place for IL-6 blockade?
New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic inflammatory myopathies, such as polymyositis and dermatomyositis. Elevated ...
来自MSN26 天
Study uncovers key factors in myositis-induced muscle weakness
A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic autoimmune disorders known for causing severe muscle weakness, fatigue ...
Yahoo Finance1 个月
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
“Idiopathic inflammatory myopathies are debilitating diseases that can cause muscle weakness, affect multiple organs, and have a severe impact on patients’ quality of life, including increased ...